Identification of the role of MED6 in the development and prognosis of lung adenocarcinoma based on multi-omics profiling

Background: Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer.Recent studies have highlighted the importance of Mediator complex subunits in cancer, but their specific roles in LUAD are still unclear.Methods: The CRISPR-Cas9 loss-of-function data was used to assess gene dependency in cell growth.RNA-seq data were analyzed to evaluate the prognostic value of Mediator subunits and explore their downstream pathways.Single-cell sequencing data were utilized to examine the tumor microenvironment in LUAD.A drug sensitivity analysis was performed to identify potential therapeutic options.Results: Mediator complex subunit 6 (MED6) was found to influence tumor cell growth in LUAD.Additionally, MED6 expression levels were associated with patient prognosis.MED6-positive tumor cells showed more active interactions with other cells in the LUAD microenvironment, promoting tumor progression.Based on MED6 expression, drugs such as paclitaxel, afatinib, and brivanib were identified as potential treatments.Conclusions: This study revealed the role of MED6 in LUAD and its potential as a biomarker.Our findings suggest that MED6 has an effect on LUAD progression and provide valuable insights for patient stratification and personalized treatment strategies.